Literature DB >> 3739918

Arginine vasopressin and the renal response to water loading in congestive heart failure.

S R Goldsmith, G S Francis, A W Cowley.   

Abstract

Previous studies have shown on the basis of isolated comparisons that plasma arginine vasopressin (AVP) levels are inappropriately increased for a given serum osmolality in patients with CHF. To explore further the osmoregulation of AVP in this condition, the response of plasma AVP to a 15- to 20-ml/kg oral water load was compared in 26 patients with CHF and 14 normal subjects. In the normal subjects, serum osmolality decreased from 289 +/- 5.0 to 282 +/- 5.0 mOsm/kg (p less than 0.001) and AVP from 3.6 +/- 1.1 to 2.1 +/- 0.78 pg/ml (p less than 0.001). In the patients with CHF, osmolality decreased from 289 +/- 7.0 to to 281 +/- 7.0 mOsm/kg and AVP from 7.1 +/- 3.6 to 5.8 +/- 3.4 pg/ml (p less than 0.001). As a percentage of the control value, the decrease in AVP was much greater in the normal group, 41 +/- 15% vs 18 +/- 10% (p less than 0.001). Urinary osmolality levels were measured before and after water loading in 11 patients and in 7 normal subjects. Normal subjects diluted from 812 +/- 130 to 133 +/- 26 mOsm/kg (p less than 0.001) and CHF patients from 599 +/- 218 to 253 +/- 170 mOsm/kg, a statistically significant (p less than 0.01) but smaller (p less than 0.05) level of suppression. There were, however, 2 distinct groups within the CHF population: one in which urine osmolality was appropriately decreased (from 594 +/- 269 to 144 +/- 37 mOsm/kg, p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3739918     DOI: 10.1016/0002-9149(86)90065-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  23 in total

1.  A reduction in SK channels contributes to increased activity of hypothalamic magnocellular neurons during heart failure.

Authors:  Hildebrando C Ferreira-Neto; Vinicia C Biancardi; Javier E Stern
Journal:  J Physiol       Date:  2017-08-02       Impact factor: 5.182

2.  Enhanced NMDA receptor-mediated intracellular calcium signaling in magnocellular neurosecretory neurons in heart failure rats.

Authors:  Javier E Stern; Evgeniy S Potapenko
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-06-19       Impact factor: 3.619

3.  Hyponatremia in heart failure: concluding remarks.

Authors:  Kanu Chatterjee
Journal:  Heart Fail Rev       Date:  2008-08-29       Impact factor: 4.214

4.  Astrocytes modulate a postsynaptic NMDA-GABAA-receptor crosstalk in hypothalamic neurosecretory neurons.

Authors:  Evgeniy S Potapenko; Vinicia C Biancardi; Yiqiang Zhou; Javier E Stern
Journal:  J Neurosci       Date:  2013-01-09       Impact factor: 6.167

Review 5.  Future pharmacologic agents for treatment of heart failure in children.

Authors:  Brady S Moffett; Anthony C Chang
Journal:  Pediatr Cardiol       Date:  2006-08-23       Impact factor: 1.655

6.  Inhibitory-excitatory synaptic balance is shifted toward increased excitation in magnocellular neurosecretory cells of heart failure rats.

Authors:  Evgeniy S Potapenko; Vinicia C Biancardi; Renea M Florschutz; Pan D Ryu; Javier E Stern
Journal:  J Neurophysiol       Date:  2011-06-22       Impact factor: 2.714

7.  An L-RNA-based aquaretic agent that inhibits vasopressin in vivo.

Authors:  Werner G Purschke; Dirk Eulberg; Klaus Buchner; Stefan Vonhoff; Sven Klussmann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-17       Impact factor: 11.205

8.  Role of vasopressin and aldosterone in pulmonary arterial hypertension: A pilot study.

Authors:  Shweta Bansal; David Badesch; Todd Bull; Robert W Schrier
Journal:  Contemp Clin Trials       Date:  2009-04-16       Impact factor: 2.226

Review 9.  Hyponatremia in patients with heart failure.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Cardiol       Date:  2013-09-26

Review 10.  Treating hyponatremia in heart failure.

Authors:  Steven R Goldsmith
Journal:  Curr Cardiol Rep       Date:  2006-05       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.